Trevi Therapeutics Shares Rise on Positive Haduvio Clinical Trial Results

Trevi Therapeutics (TRVI) shares increased by 9.85% following positive clinical trial results for its treatment candidate, Haduvio, which targets chronic cough and idiopathic pulmonary fibrosis. The company highlighted the drug's potential to access a $14-15 billion market by 2035.

By Angelica Ballesteros Sat, July 18, 2026 at 5:20 AM GMT+3 3 min read · Yahoo Finance · July 18, 2026, 02:20 UTC

Trevi Therapeutics Shares Rise on Positive Haduvio Clinical Trial Results

Tickers: $TRVI

Topics: chronic_cough drug_development market_opportunity

Read the full article at Yahoo Finance

More World news

Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC
Alvotech Shares Decline Following Third Quarter Earnings Miss Seeking Alpha · November 12, 2026, 19:05 UTC
Saga Communications Projects $5.7 Million in 2026 Political Revenue Amid Q4 Growth Seeking Alpha · November 12, 2026, 19:00 UTC
Corteva Forecasts 2026 Operating EBITDA Between $1.1B and $1.125B Amid Brazilian Market Pressures Seeking Alpha · November 12, 2026, 19:00 UTC
DPC Holdings PLC Reports Record Q3 Revenue Growth and Issues 2027 Financial Guidance Seeking Alpha · November 12, 2026, 19:01 UTC